JP2006516652A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516652A5
JP2006516652A5 JP2006503317A JP2006503317A JP2006516652A5 JP 2006516652 A5 JP2006516652 A5 JP 2006516652A5 JP 2006503317 A JP2006503317 A JP 2006503317A JP 2006503317 A JP2006503317 A JP 2006503317A JP 2006516652 A5 JP2006516652 A5 JP 2006516652A5
Authority
JP
Japan
Prior art keywords
composition
peptide
amino acids
minimum
net positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006503317A
Other languages
English (en)
Japanese (ja)
Other versions
JP4838114B2 (ja
JP2006516652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/003193 external-priority patent/WO2004070054A2/en
Publication of JP2006516652A publication Critical patent/JP2006516652A/ja
Publication of JP2006516652A5 publication Critical patent/JP2006516652A5/ja
Application granted granted Critical
Publication of JP4838114B2 publication Critical patent/JP4838114B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006503317A 2003-02-04 2004-02-03 ミトコンドリア透過性転移の阻止方法 Expired - Lifetime JP4838114B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US60/444,777 2003-02-04
US53569004P 2004-01-08 2004-01-08
US60/535,690 2004-01-08
PCT/US2004/003193 WO2004070054A2 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010241738A Division JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法

Publications (3)

Publication Number Publication Date
JP2006516652A JP2006516652A (ja) 2006-07-06
JP2006516652A5 true JP2006516652A5 (enExample) 2007-10-18
JP4838114B2 JP4838114B2 (ja) 2011-12-14

Family

ID=32853391

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2006503317A Expired - Lifetime JP4838114B2 (ja) 2003-02-04 2004-02-03 ミトコンドリア透過性転移の阻止方法
JP2010241738A Expired - Lifetime JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法
JP2013182343A Expired - Lifetime JP5837542B2 (ja) 2003-02-04 2013-09-03 ミトコンドリア透過性転移の阻止方法
JP2014202889A Expired - Lifetime JP6126059B2 (ja) 2003-02-04 2014-10-01 ミトコンドリア透過性転移の阻止方法
JP2015135207A Expired - Lifetime JP6166312B2 (ja) 2003-02-04 2015-07-06 ミトコンドリア透過性転移の阻止方法
JP2017025764A Pending JP2017095519A (ja) 2003-02-04 2017-02-15 ミトコンドリア透過性転移の阻止方法
JP2019001256A Pending JP2019089773A (ja) 2003-02-04 2019-01-08 ミトコンドリア透過性転移の阻止方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2010241738A Expired - Lifetime JP5775285B2 (ja) 2003-02-04 2010-10-28 ミトコンドリア透過性転移の阻止方法
JP2013182343A Expired - Lifetime JP5837542B2 (ja) 2003-02-04 2013-09-03 ミトコンドリア透過性転移の阻止方法
JP2014202889A Expired - Lifetime JP6126059B2 (ja) 2003-02-04 2014-10-01 ミトコンドリア透過性転移の阻止方法
JP2015135207A Expired - Lifetime JP6166312B2 (ja) 2003-02-04 2015-07-06 ミトコンドリア透過性転移の阻止方法
JP2017025764A Pending JP2017095519A (ja) 2003-02-04 2017-02-15 ミトコンドリア透過性転移の阻止方法
JP2019001256A Pending JP2019089773A (ja) 2003-02-04 2019-01-08 ミトコンドリア透過性転移の阻止方法

Country Status (13)

Country Link
US (8) US7576061B2 (enExample)
EP (9) EP3659618A1 (enExample)
JP (7) JP4838114B2 (enExample)
CN (3) CN102784383B (enExample)
AU (1) AU2004209663B2 (enExample)
CA (1) CA2515080C (enExample)
CY (2) CY1114959T1 (enExample)
DK (3) DK1599216T3 (enExample)
ES (3) ES2436011T3 (enExample)
HU (1) HUE027110T2 (enExample)
PT (2) PT1599216E (enExample)
SI (1) SI2656854T1 (enExample)
WO (1) WO2004070054A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
CA2947330C (en) * 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
CA2713150C (en) 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
WO2011091357A1 (en) * 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2547352A4 (en) * 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
US20110245183A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
JP6319738B2 (ja) * 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
EP2688579A4 (en) * 2011-03-24 2015-10-21 Univ Cornell CATIONIC AROMATIC PEPTIDES AND USES THEREOF
HK1200459A1 (en) * 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
CA2852454A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
EP3466439A1 (en) 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
JP2015524439A (ja) * 2012-08-02 2015-08-24 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
ES3058737T3 (en) * 2012-10-22 2026-03-12 Stealth Biotherapeutics Inc Treatment of left ventricular remodeling
ES2750258T3 (es) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Métodos y composiciones para la prevención o tratamiento del síndrome de Barth
CN117752766A (zh) * 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20160166633A1 (en) 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
EP3154694B1 (en) 2014-06-13 2025-01-29 Children's Medical Center Corporation Products and methods to isolate mitochondria
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
PL3160985T3 (pl) 2014-06-30 2021-12-27 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylo-l-fenyloalaninoamidu
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
WO2016069556A2 (en) 2014-10-29 2016-05-06 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
ES3057779T3 (en) 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
JP7038675B2 (ja) * 2016-03-11 2022-03-18 ステルス バイオセラピューティクス インコーポレイテッド 結晶塩形態
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2018100893A1 (ja) 2016-11-30 2018-06-07 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP3668837B1 (en) 2017-08-17 2022-07-06 XWPharma Ltd. Preparation and uses of reactive oxygen species scavenger derivatives
EP3988561B1 (en) 2017-09-04 2023-06-07 XWPharma Ltd. Preparation and use of reactive oxygen species scavenger
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
IL284006B2 (en) * 2018-12-18 2024-12-01 Stealth Biotherapeutics Corp Mitochondria-targeting peptides
WO2020222866A1 (en) * 2019-05-02 2020-11-05 Children's Medical Center Corporation Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
KR20240073137A (ko) * 2020-09-09 2024-05-24 소셜 프로핏 네트워크 미토콘드리아에 비오틴의 전달을 위한 방법 및 조성물
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
WO1991010361A1 (en) * 1990-01-17 1991-07-25 The Regents Of The University Of California Composition to improve survival of biological materials
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
ATE240728T1 (de) * 1996-10-07 2003-06-15 Lilly Co Eli Neue verbindungen nutlich als neuroschützende mittel
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
WO2001025188A1 (en) * 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
CA2416475C (en) * 2000-07-18 2011-10-11 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
JP2004523490A (ja) * 2000-11-28 2004-08-05 ギルフォード ファーマシュウティカルズ インコーポレイテッド 二置換カルボサイクリックサイクロフィリン結合化合物とその用途
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
MXPA03006666A (es) * 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US6942681B2 (en) * 2001-02-16 2005-09-13 Cordis Corporation Method of balloon catheter stent delivery system with ridges
JP2004526499A (ja) * 2001-03-16 2004-09-02 エスティーエス バイオポリマーズ，インコーポレイティド 複数層ポリマーコーティングを有する薬物添加ステント
WO2002102833A1 (fr) * 2001-06-15 2002-12-27 Senju Pharmaceutical Co., Ltd. Nouveaux derives d'endomorphine
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN100536909C (zh) * 2003-02-04 2009-09-09 科内尔研究基金会 用于防止线粒体通透性改变的方法
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
CA2947330C (en) 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression

Similar Documents

Publication Publication Date Title
CA2515080A1 (en) Methods for preventing mitochondrial permeability transition
RU2006130431A (ru) Способ уменьшения окислительного повреждения (варианты)
JP2007518818A5 (enExample)
Schiller et al. Synthesis and in vitro opioid activity profiles of DALDA analogues
US6320024B1 (en) Method for design of substances that enhance memory and improve the quality of life
JP2003503312A5 (enExample)
US20120101037A1 (en) Glucose-dependent insulinotropic peptide analogs
WO2002026774A2 (en) Melanocortin receptor ligands
AU2001296313A1 (en) Melanocortin receptor ligands
IL191636A (en) Neurolipeptide-2 receptor agonists, medicinal preparations containing them and their use in the preparation of drugs
IL224609A (en) Intact and peptide intestinal fragments and methods of use
CN102574894A (zh) 稳定化的黑皮质素配体
RU2010111114A (ru) Нейропротективное действие с применением nap-подобных и sal-подобных пептидных миметиков
JP2837352B2 (ja) 胃腸運動活性を抑制するモチリン類似ポリペプチド
US9611297B1 (en) Compositions and methods for the treatment of cast nephropathy and related conditions
Yasuda-Kamatani et al. A novel D-amino acid-containing peptide, fulyal, coexists with fulicin gene-related peptides in Achatina atria
Ghosh et al. Breaker peptides against amyloid-β aggregation: a potential therapeutic strategy for Alzheimer’s disease
JP2009519212A5 (enExample)
CA2769013C (en) Motilin-like peptide compound having transmucosal absorbability imparted thereto
M Cowell et al. Biphalin: the foundation of bivalent ligands
JP6795258B2 (ja) 医薬化合物
CN115298194A (zh) Vipr2拮抗肽
IE903958A1 (en) Reduced irreversible bombesin antagonists
Mukai et al. Structure-activity relationships of mammalian bombesin-like neuropeptides in the contraction of rat uterus
Mansfeld et al. Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives